{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:49:49Z","timestamp":1770684589653,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2011,7,1]],"date-time":"2011-07-01T00:00:00Z","timestamp":1309478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T00:00:00Z","timestamp":1574380800000},"content-version":"vor","delay-in-days":3066,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1093\/annonc\/mdq635","type":"journal-article","created":{"date-parts":[[2011,1,7]],"date-time":"2011-01-07T02:08:04Z","timestamp":1294366084000},"page":"1595-1600","source":"Crossref","is-referenced-by-count":71,"title":["Intensified alemtuzumab\u2013CHOP therapy for peripheral T-cell lymphoma"],"prefix":"10.1016","volume":"22","author":[{"given":"H.C.","family":"Kluin-Nelemans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"van Marwijk Kooy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.J.","family":"Lugtenburg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.L.J.","family":"van Putten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Luten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Oudejans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.W.","family":"van Imhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq635_bb0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO;2-B","article-title":"Peripheral T-cell lymphoma","volume":"63","author":"Armitage","year":"1989","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq635_bb0015","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"Non-Hodgkins lymphoma Classif Proj. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes","volume":"16","author":"Armitage","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0020","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11864-004-0020-8","article-title":"Treatment of T-cell non-Hodgkin's lymphoma","volume":"5","author":"Evens","year":"2004","journal-title":"Curr Treat Options Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0030","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0035","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq635_bb0040","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1385\/MO:19:2S:S27","article-title":"Alemtuzumab in T-cell malignancies","volume":"19","author":"Dearden","year":"2002","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0045","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","article-title":"Campath-1H treatment of T-Cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed","volume":"20","author":"Keating","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0050","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.1997.15.7.2667","article-title":"Treatment of T-cell prolymphocytic leukemia with human CD52 antibody","volume":"15","author":"Pawson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0055","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1200\/JCO.2009.22.6688","article-title":"Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0060","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0065","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/jcp.2008.055335","article-title":"Peripheral T-cell lymphoma not otherwise-specified: the stuff of genes, dreams and therapies","volume":"61","author":"Agostinelli","year":"2008","journal-title":"J Clin Pathol"},{"key":"10.1093\/annonc\/mdq635_bb0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematol"},{"key":"10.1093\/annonc\/mdq635_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"10.1093\/annonc\/mdq635_bb0080","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0085","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood-2003-06-2095","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0090","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","article-title":"Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL","volume":"104","author":"Pfreundschuh","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0095","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0100","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0105","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.2307\/2533268","article-title":"Incorporating toxicity considerations into the design of two-stage phase II clinical trials","volume":"51","author":"Bryant","year":"1995","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdq635_bb0110","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2008-02-138800","article-title":"EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma","volume":"112","author":"Kluin-Nelemans","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0115","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq635_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdq635_bb0125","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bmt.2008.332","article-title":"Hematopoietic SCT for peripheral T-cell lymphoma","volume":"42","author":"Guti\u00e9rrez","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdq635_bb0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/asheducation-2008.1.289","article-title":"Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas","volume":"2008","author":"Horwitz","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1093\/annonc\/mdq635_bb0135","first-page":"218","article-title":"High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Kyriakou","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0140","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0150","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11899-009-0031-4","article-title":"Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?","volume":"4","author":"D\u2032Amore","year":"2009","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1093\/annonc\/mdq635_bb0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10428190601016167","article-title":"CD52 expression in non-mycotic T- and NK\/T-cell lymphomas","volume":"48","author":"Chang","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq635_bb0160","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdq635_bb0165","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq635_bb0170","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1080\/10428190902926981","article-title":"CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies","volume":"50","author":"Geissinger","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq635_bb0175","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1080\/10428190802475303","article-title":"Pharmacokinetics of alemtuzumab and the relevance in clinical practice","volume":"49","author":"Elter","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdq635_bb0180","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/archinte.163.17.1997","article-title":"Posttransplantation lymphoproliferative disorders","volume":"163","author":"Andreone","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1093\/annonc\/mdq635_bb0185","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3324\/haematol.11272","article-title":"Post-transplant lymphoproliferative disorders: from treatment to early detection and prevention?","volume":"92","author":"Bakker","year":"2007","journal-title":"Haematol"},{"key":"10.1093\/annonc\/mdq635_bb0190","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12185-008-0176-2","article-title":"Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma","volume":"88","author":"Weisel","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1093\/annonc\/mdq635_bb0195","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.11871","article-title":"Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia","volume":"98","author":"O\u2032Brien","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq635_bb0200","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2009.24.4194","article-title":"Epstein-Barr virus-positive diffuse large B-Cell lymphoma during therapy with alemtuzumab for T-Cell prolymphocytic leukemia","volume":"28","author":"Sohani","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq635_bb0205","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1309\/6UTX-GVC0-12ND-JJEU","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders in angloimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified","volume":"117","author":"Zettl","year":"2002","journal-title":"Am J Clin Pathol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419384364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/22\/7\/1595\/459437\/mdq635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:22:30Z","timestamp":1636669350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419384364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["S0923753419384364"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq635","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}